Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, 00168, Italy
NCT Number: NCT06806683
The ITHACA study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient. This tool uses information such as medical history, imaging, and radiotherapy data to predict the risk of cancer recurrence, overall survival, and the likelihood of side effects.
Patients with head and neck cancer face significant challenges, including managing the side effects of treatments like radiotherapy. By tailoring treatment schedules and doses, and using advanced imaging techniques, we hope to reduce complications and improve survival outcomes. The study is designed to help doctors choose the best treatment for each patient, while minimizing the side effects that impact important functions like swallowing and breathing.
Patients participating in the study will have their medical data collected, including:
Tumor characteristics (size, location, stage). Treatment details (radiotherapy and chemotherapy). Imaging information using tools like PET-CT and MRI to track the response to treatment and detect any signs of cancer recurrence.
Side effects and overall health data. This information will be used to develop and test a new model that predicts outcomes for each patient based on their unique data.
The study includes adults (18 years and older) diagnosed with head and neck cancer, who are undergoing or have completed radiotherapy. Patients will be followed over time to monitor their response to treatment and any side effects.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Rome, Lazio, 00168, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must meet all of the following criteria:
Exclusion criteria
Participants will be excluded if they meet any of the following criteria:
intensity modulated radiotherapy
Time frame: From enrollment to 36 months post-treatment
The main focus is the probability of recurrence of head and neck cancer after the completion of radiotherapy. This will be assessed at various intervals, specifically at 3, 6, 12, 24, and 36 months post-treatment, using imaging techniques such as PET-CT, MRI, and CT, along with clinical evaluations.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
ITHACA: Development and Validation of a Multivariate Predictive Model for Prognosis in Head and Neck Cancer Patients Undergoing Radiotherapy - Ambispective Study.
Acronym: ITHACA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07241273
Carcinoma, Carcinoma, Squamous Cell
Brest, France
View Trial DetailsNCT03556228
Adenocarcinoma, Adenoid Cystic Carcinoma
Santa Rosa, California, United States
View Trial DetailsNCT06719388
Head and Neck Cancers, Head and Neck Neoplasms
Taipei, Taiwan
View Trial DetailsNCT00186433
Head and Neck Cancers, Head and Neck Neoplasms
Stanford, California, United States
View Trial Details